

November 16, 2018

Listing Department  
**BSE LIMITED**  
P J Towers, Dalal Street, Fort,  
Mumbai-400 001

**Code: 532 321**

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai-400 051

**Code: CADILAHC**

Re.: **Press Release**

Dear Sir / Madam,

Please find enclosed a copy of press release dated November 16, 2018 titled "Zydus receives final approval from the USFDA for Abacavir & Lamivudine Tablets and Fondaparinux Sodium Injection".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For, **CADILA HEALTHCARE LIMITED**

  
**UPEN H. SHAH**  
**COMPANY SECRETARY**



Encl.: As above

## **Zydus receives final approval from the USFDA for Abacavir & Lamivudine Tablets and Fondaparinux Sodium Injection**

*Ahmedabad, 16 November, 2018*

Zydus Cadila has received the final approval from the USFDA to market Abacavir and Lamivudine Tablets USP, 600 mg/300 mg (US RLD – EPZICOM), and Fondaparinux Sodium Injection USP, 2.5 mg/0.5 mL, 5 mg/0.4 mL 7.5 mg/0.6 mL and 10 mg/0.8 mL single-dose (US RLD – ARIXTRA).

Abacavir and Lamivudine Tablets are used with other antiretroviral medicines to treat Human Immunodeficiency Virus-type 1 (HIV-1) infection. HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS). It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

Fondaparinux Injection is used to treat blood clots in deep veins (deep vein thrombosis) and the lungs (pulmonary embolism). It can also be used to prevent blood clots in patients undergoing certain types of surgeries. It will be manufactured at a partner's manufacturing site.

The group now has more than 230 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*